CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-18 | Zalevsky Jonathan Chief R&D Officer | Sale | −186 | $71.98 | $13K | 9,570 |
| 2026-07-24 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +16,500 | 16,500 | ||
| 2026-06-30 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −5,681 | $70.00 | $398K | 9,756 |
| 2026-06-15 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −5,538 | $60.71 | $336K | 15,437 |
| 2026-05-19 | Zalevsky Jonathan Chief R&D Officer | Sale | −199 | $65.51 | $13K | 20,975 |
| 2026-02-18 | Zalevsky Jonathan Chief R&D Officer | Sale | −180 | $73.00 | $13K | 21,174 |
| 2026-01-20 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −3,867 | $35.67 | $138K | 21,354 |
| 2025-12-22 | Zalevsky Jonathan Chief R&D Officer | Grant or award | +6,250 | 25,221 | ||
| 2025-12-22 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +25,000 | 25,000 | ||
| 2025-11-25 | Zalevsky Jonathan Chief R&D Officer | Sale | −1,157 | $54.28 | $63K | 18,971 |
| 2025-11-21 | Zalevsky Jonathan Chief R&D Officer | Grant or award | +2,666 | 20,128 | ||
| 2025-11-21 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +4,766 | 4,766 | ||
| 2025-09-04 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −793 | $32.43 | $26K | 18,390 |
| 2025-09-04 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −432 | $33.60 | $15K | 17,958 |
| 2025-09-04 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −189 | $34.41 | $7K | 17,769 |
| 2025-09-04 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −307 | $35.69 | $11K | 17,462 |
| 2025-09-02 | Zalevsky Jonathan Chief R&D Officer | Sale 10b5-1 | −485 | $30.10 | $15K | 19,183 |
| 2025-08-19 | Zalevsky Jonathan Chief R&D Officer | Sale | −725 | $26.59 | $19K | 19,668 |
| 2025-08-19 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +16,666 | 16,666 | ||
| 2025-05-19 | Zalevsky Jonathan Chief R&D Officer | Sale | −10,712 | $0.67 | $7K | 305,892 |
Page 1 of 4 · 63 trades